The invariant chain, originally identified as an essential chaperone for major histocompatibility complex class II molecules, has emerged as a versatile signaling hub. Today, evaluating CD74 in hematological malignancies provides critical insights into tumor survival pathways, immune evasion, and novel targeted therapeutic platforms for oncologists and hematologists worldwide.

Biological Function and Structure of CD74

Under normal physiological conditions, CD74 is a type II transmembrane glycoprotein that directs antigen presentation. In the endoplasmic reticulum, CD74 trimers associate with MHC class II dimers to prevent premature peptide loading. Furthermore, CD74 guides these complexes through the Golgi apparatus toward endolysosomal compartments. Endosomal proteases then degrade CD74, leaving the class II-associated invariant chain peptide within the binding cleft.

Additionally, CD74 translocates independently to the plasma membrane in molar excess. On the cell surface, CD74 serves as the primary receptor for macrophage migration inhibitory factor. Upon ligand engagement, CD74 activates downstream signaling networks that govern normal B-cell differentiation, dendritic cell motility, and macrophage polarization. Moreover, intramembrane cleavage releases the CD74 intracellular domain to regulate transcription, establishing CD74 as a central coordinator of physiological immunity.

Signaling Role of CD74 in Hematological Malignancies

The oncogenic impact of CD74 in hematological malignancies relies on its extensive downstream survival signaling. When macrophage migration inhibitory factor engages cell-surface CD74, the receptor forms a multi-protein signaling complex with CD44. This molecular assembly triggers the activation of spleen tyrosine kinase and the phosphoinositide 3-kinase/protein kinase B pathway, conferring marked apoptosis resistance to malignant cells.

Furthermore, CD74 engagement stimulates both canonical and non-canonical nuclear factor kappa B cascades. Nuclear translocation of the cleaved intracellular domain directly upregulates key pro-survival factors, including Bcl-2 family members and cyclin D1. Consequently, neoplastic clones exhibit accelerated proliferation and heightened metabolic fitness. Additionally, CD74 signaling remodels the microenvironment by recruiting regulatory T cells and promoting M2 macrophage polarization, effectively shielding tumors from host immune surveillance.

Expression Patterns in Lymphomas, Leukemias, and Myeloma

Translational research confirms that CD74 is abundantly expressed across diverse hematologic neoplasms. In B-cell non-Hodgkin lymphomas, such as diffuse large B-cell lymphoma and mantle cell lymphoma, malignant cells exhibit universal surface expression. Similarly, classical Hodgkin lymphoma, cutaneous T-cell lymphoma, and chronic lymphocytic leukemia demonstrate consistent CD74 upregulation compared to non-malignant tissues.

In multiple myeloma, malignant plasma cells maintain strong CD74 expression despite the loss of mature B-cell markers like CD19. High receptor density often correlates with advanced clinical stages and extensive marrow involvement. Moreover, blast populations in acute leukemias frequently display surface CD74. In contrast, healthy non-hematopoietic tissues express minimal CD74, creating a wide therapeutic index. Because CD74 internalizes rapidly upon antibody binding, it serves as an optimal target for selective cancer therapeutics.

Novel Therapeutic Strategies Targeting CD74

The rapid endocytosis and selective expression of CD74 have accelerated the development of targeted therapies. Antibody-drug conjugates represent a leading modality in this landscape. Modern anti-CD74 antibody-drug conjugates deliver potent cytotoxic agents, such as maytansinoids, directly into malignant lymphocytes. Following receptor internalization, lysosomal processing releases the payload, causing selective mitotic catastrophe while sparing adjacent healthy tissues.

Furthermore, bioengineers are actively advancing bispecific antibodies and chimeric antigen receptor T-cell platforms targeting CD74. Bispecific constructs simultaneously engage CD74 and CD3, redirecting host cytotoxic T lymphocytes to destroy tumor cells. Similarly, anti-CD74 CAR-T therapies demonstrate potent cytolytic activity and durable tumor regression in preclinical mantle cell lymphoma and myeloma models. Consequently, these diverse therapeutic formats provide versatile options for addressing refractory hematologic diseases.

Mechanisms of Resistance and Combinatorial Solutions

Although CD74-directed therapies show substantial promise, malignant clones can develop adaptive resistance mechanisms. Chronic therapeutic pressure may induce CD74 downregulation or promote alternative splicing. Additionally, elevated concentrations of circulating macrophage migration inhibitory factor and shed CD74 can act as decoy receptors, neutralizing therapeutic antibodies in the circulation.

Moreover, cancer cells frequently activate compensatory signaling pathways, such as the JAK/STAT cascade, when CD74 signaling is blocked. Residual myeloma clones surviving BCMA-targeted CAR-T therapy often upregulate CD74 to maintain survival under immune pressure. To overcome these resistance mechanisms, clinicians are exploring rational combinatorial strategies. Combining CD74-targeted agents with proteasome inhibitors, immunomodulatory drugs, or checkpoint inhibitors disrupts compensatory pathways and enhances anti-tumor efficacy, ensuring more durable clinical responses.

Future Clinical Directions in Precision Hematology

Integrating CD74-targeted therapeutics into routine clinical practice requires standardized diagnostic workflows. Developing validated immunohistochemistry and flow cytometry panels will allow precise quantification of CD74 density, helping clinicians select patients most likely to benefit from internalizing antibody-drug conjugates or cellular immunotherapies.

Furthermore, ongoing clinical trials are evaluating next-generation anti-CD74 antibodies with optimized Fc regions to enhance antibody-dependent cellular cytotoxicity. Combining these novel constructs with standard chemotherapy or immune checkpoint inhibitors offers compelling synergy. As precision hematology continues to advance, CD74 represents a highly promising and actionable biomarker across multiple lymphoid and myeloid malignancies, paving the way for more effective personalized interventions.

Frequently Asked Questions

What physiological role does CD74 serve in immune cells?

CD74 primarily functions as an essential invariant chaperone that directs major histocompatibility complex class II trafficking and prevents premature antigen binding within endosomal compartments. Additionally, surface CD74 acts as a receptor for macrophage migration inhibitory factor. Through this pathway, CD74 stimulates intracellular signaling cascades that regulate normal B-cell maturation, survival, dendritic cell motility, and inflammatory responses across healthy tissues.

Why is CD74 an attractive target for antibody-drug conjugates?

CD74 exhibits exceptionally rapid receptor-mediated internalization and continuous surface turnover following antibody engagement. When an engineered antibody-drug conjugate binds to CD74, the complex is swiftly shuttled into intracellular lysosomes. Consequently, lysosomal enzymes cleave the linker, releasing potent cytotoxic payloads directly within the malignant cell. This mechanism maximizes tumor cell eradication while sparing normal tissues from unnecessary systemic toxicity.

How does CD74 contribute to multiple myeloma progression and resistance?

In multiple myeloma, malignant plasma cells consistently express elevated CD74 levels, which activates downstream NF-kappaB and PI3K/Akt pathways to promote survival and proliferation. Furthermore, translational research reveals that CD74 upregulation in residual myeloma clones mediates escape from BCMA-targeted CAR-T cell therapies. Therefore, therapeutically targeting CD74 provides a valuable strategy to overcome treatment resistance and improve patient outcomes.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Zhang S et al. CD74 in hematological malignancies: from MHC chaperone to therapeutic target. Leuk Lymphoma. 2026 Aug 30. doi: 10.1080/10428194.2026.2721032. PMID: 42669181.
2. Chen X, Zhang J, Chen H, et al. Targeting CD74 may mitigate immune-escape features and enhance BCMA CAR-T activity in preclinical models of relapsed/refractory multiple myeloma. J Immunother Cancer. 2026;14(5):e013255.
3. Li X, Abrahams C, Yu A, et al. Targeting CD74 in B-cell non-Hodgkin lymphoma with the antibody-drug conjugate STRO-001. Oncotarget. 2023;14:14-27.